Industry News

Peregrine Pharmaceuticals Inc., PTC Therapeutics Inc., Aratana Therapeutics Inc., and Vanda Pharmaceuticals Inc.. According to a new report by Grand View Research, the global white biotechnology market is expected to grow at a CAGR of 10.2% from 2016 to 2024, while the biofuels segment is forecasted to grow at a CAGR of more than 9% over the same period."/>
Biotech Stocks Technical Reports -- Peregrine Pharma, PTC Therapeutics, Aratana Therapeutics, and Vanda Pharma
Aceto Corporation, the leader in the marketing, sales and distribution of specialty chemicals in the U.S., announced an agreement for sales and distribution of Verdezyne's BIOLON ® DDDA. BIOLON DDDA will be produced by Verdezyne and will be distributed in the United States of America by Aceto. Verdezyne's BIOLON DDDA is produced more..."/>
Verdezyne Signs Distribution Agreement With Aceto Corporation
Catabasis Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, today announced the promotion of Andrew Nichols, Ph.D. to Chief Scientific Officer and Angelika Fretzen, Ph.D., to Senior Vice President of Product Development. Nichols has more than 25 years of drug development experience, leading efforts from target discovery through translational research and early clinical development for pharmaceutical and biotechnology companies."/>
Catabasis Pharmaceuticals Announces Promotion of Andrew Nichols, Ph.D. to Chief Scientific Officer and Angelika Fretzen to Senior Vice President of Product Development
Fate Therapeutics, Inc., a biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer and immune disorders, announced today that the U.S."/>
Fate Therapeutics Announces Issuance of U.S. Patent Protecting Enhanced Hematopoietic Stem Cell Compositions
CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing therapies to treat metabolic diseases with high unmet medical need, today announced that after receiving input from the U.S. Food and Drug Administration, it has determined the next step in the development of MBX-8025 in subjects with primary biliary cholangitis. MBX-8025 is an orally administered potent and selective peroxisome..."/>
CymaBay Therapeutics Announces Plans to Initiate Its Next Phase 2 Study of MBX-8025 in Primary Biliary Cholangitis
Repligen Corporation, a life sciences company focused on bioprocessing technology leadership, today announced the commercial launch of its single-use version of XCell™ ATF, a proprietary cell retention..."/>
Repligen Launches Single-Use XCell™ ATF System for Bioprocess Intensification
Immunomedics, Inc., today announced that it has priced an underwritten offering of 10,000,000 shares of common stock and warrants to purchase up to 10,000,000 shares of common stock with anticipated gross proceeds of $30 million. Each share of common stock and accompanying warrant will be priced at $3.00. The warrants will be exercisable six months following the date of issuance, will expire on the second anniversary of the date of issuance and..."/>
Immunomedics Announces $30 Million Financing
Profound Medical Corp., an emerging medical device company focused on prostate care, announced today that it has received Frost& Sullivan’ s 2016 European Prostate Ablation Systems New Product Innovation Award for its TULSA-PRO TM system.. TULSA-PRO, which received CE Mark approval in April 2016, combines real-time Magnetic Resonance Imaging with transurethral, robotically-driven therapeutic ultrasound and closed-loop thermal feedback control..."/>
Profound Medical Receives Frost & Sullivan’s 2016 New Product Innovation Award
NanoString Technologies, Inc., a provider of life science tools for translational research and molecular diagnostic products, today announced that the Company will release third quarter 2016 financial results after the close of trading on Wednesday, November 2, 2016. Company management will host a conference call beginning at 4:30pm ET to discuss those results and provide a business update.. Individuals interested in listening to the conference call..."/>
NanoString Technologies to Release Third Quarter 2016 Financial Results and Host Conference Call on Wednesday, November 2, 2016
DiaMedica Inc. announced that the first patient has been dosed in the Phase Ib clinical trial of DM199, a novel recombinant tissue kallikrein protein for the development of neurological and kidney diseases. "Dosing the first patient in the DM199 study represents another important step toward our goal of providing patients and physicians with treatment options for the currently unaddressed complications of stroke and kidney diseases," said..."/>
DiaMedica Announces First Patient Enrolled in Bridging Clinical Trial for DM199
TapImmune Inc., a clinical-stage immuno-oncology company specializing in the development of innovative peptide and gene-based immunotherapeutics and vaccines for the treatment of cancer& metastatic disease, today announced its President and Chief Operating Officer, Dr. John Bonfiglio, will be a speaker and deliver a corporate presentation at the BioNetwork Partnering Summit on Wednesday, October 5 at 4:35 PM PT."/>
TapImmune President Dr. John Bonfiglio to Present at BioNetwork Partnering Summit on October 5, 2016
Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced the appointment of Timothy M. Wright, M.D. as Chief Research and Development Officer reporting to Paul Grint, M.D., President and CEO. Dr. Wright will oversee Regulus' research, drug discovery, clinical development, and regulatory affairs functions. "Tim brings over 30 years of academic and..."/>
Regulus Appoints Timothy M. Wright, M.D. as Chief Research and Development Officer
Teligent, Inc., a New Jersey-based specialty generic pharmaceutical company, today announced that its Estonian subsidiary, Teligent OÜ, has received approval from Health Canada's Therapeutic Products Directorate for Lidocaine Ointment USP 5%. This is the sixth approval for Teligent OÜ this calendar year and will be distributed by Teligent's business in Canada. Based on internal estimates, the total addressable market for this product is..."/>
Second Teligent Topical Product Approved by Health Canada
Collegium Pharmaceutical, Inc. announced today that it has submitted a Supplemental New Drug Application to the U.S. Food& Drug Administration to enhance the label for Xtampza ® ER, an abuse-deterrent, extended-release opioid, for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.. The sNDA includes comparative oral pharmacokinetic data..."/>
Collegium Submits Supplemental New Drug Submission to FDA for Xtampza® ER
Abeona Therapeutics Inc.. ABO-102 delivers first-in-man AAV-based gene therapy administered by single intravenous injection to treat CNS and peripheral manifestations of Sanfilippo syndrome type A Data Safety Monitoring Board approves ABO-102 dose escalation for the high-dose cohort. Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing gene therapies for life-threatening rare..."/>
Abeona Therapeutics Announces Data Safety Monitoring Board Approves ABO-102 Dose Escalation for Second Cohort in Phase 1/2 Clinical Trial for Sanfilippo Syndrome Type A
AstraZeneca today announced new data demonstrating that respiratory syncytial virus hospitalization rates increased significantly during the 2014-2015 RSV season among US infants 1 RSV is a contagious, seasonal respiratory virus that can lead to a serious lung infection and hospitalization in high-risk..."/>
New Study Shows Increases in RSV Hospitalization among High-Risk Preterm Infants
BioDelivery Sciences International, Inc. announced additions to its Board of Directors. Timothy C. Tyson will join the BDSI Board of Directors as an independent member, and Dr. Mark A. Sirgo, BDSI's President and Chief Executive Officer and board member, will, in addition to his current positions, assume the role of Vice Chairman."/>
BioDelivery Sciences Announces Additions to its Board of Directors
CytoSorbents Corporation, a therapeutic device company commercializing its CytoSorb ® blood purification cartridge to control deadly inflammation in critically-ill and cardiac surgery patients, announced positive top-line safety data from its recently completed randomized, controlled REFRESH I cardiac surgery feasibility and safety trial. Following a detailed review of all reported adverse events in a total of 46..."/>
CytoSorbents Announces Positive Top-line Safety Data from REFRESH I Cardiac Surgery Trial
EnteroMedics Inc., the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announced that vBloc ® Neurometabolic Therapy is now available to U.S. veterans at U.S. Department of Veterans Affairs medical facilities. This is made possible through the previously-announced EnteroMedics partnership with Academy Medical, LLC, a certified..."/>
EnteroMedics Announces Partner's National VA Contract Includes vBloc® Therapy for the Treatment of Obesity
Lexicon Pharmaceuticals, Inc. today announced that it has entered into an agreement to buy out its remaining obligations under its clinical development financing arrangement with Symphony Icon Holdings LLC upon regulatory approval in the United States for the marketing and sale of telotristat ethyl. "In light of progress in the process of regulatory review of telotristat ethyl for carcinoid syndrome, we felt this would be an..."/>
Lexicon Pharmaceuticals Announces Agreement To Buy Out Remaining Obligations To Symphony Icon
Capricor Therapeutics, Inc., a clinical-stage biotechnology company developing biological therapies for cardiac and other serious medical conditions, today announced that its Phase II ALLSTAR clinical trial has completed patient enrollment. ALLSTAR is evaluating CAP-1002 in adults with cardiac dysfunction following a large heart attack. "As we and others have shown, CAP-1002 possesses the ability to promote therapeutic regeneration..."/>
Capricor Therapeutics Completes Enrollment in Phase II ALLSTAR Clinical Trial
Intellia Therapeutics, Inc., a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, announced that Chief Medical Officer John Leonard, M.D., will participate in a panel discussion and present a company overview at the Jefferies Gene Editing/Therapy Summit on Tuesday, October 11, 2016.. Details of the presentation are as follows:. Jefferies Gene Editing/Therapy Summit Date:..."/>
Intellia Therapeutics to Present at Jefferies Gene Editing/Therapy Summit

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Information Technology673 Articles
Consumer Discretionary644 Articles
Financials598 Articles
Industrials439 Articles
Health Care431 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at